Ph– B-Cell ALL Achieves MRD Negativity With Inotuzumab Plus Hyper-CVAD and Blinatumomab

News
Article

Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.

Patients with Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic lymphoma (ALL) in the first-line setting were more likely to experience minimal residual disease (MRD) negativity and prolonging overall survival (OS) when inotuzumab (Besponsa) was added to hyper-CVAD and sequential blinatumomab (Blincyto), according to results of a phase 1/2 study (NCT01371630) that were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

In a poster presented by Nicholas J. Short, MD of the University of Texas MD Anderson Cancer Center during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, hyper-CVAD with sequential blinatumomab and inotuzumab achieved a 95% MRD negativity rate and a 3-year OS rate of 85%.

Typical outcomes with standard therapy for ALL include a long-term OS rate between 40% and 50% and a complete response (CR) rate between 80% and 90%. In comparison with chemotherapy, investigators know that blinatumomab plus inotuzumab has higher rates of MRD eradication, and by adding the combination to hyper-CVAD, it was hypothesized that patients would experience higher efficacy and rates of remission with less myelosuppression.

Fifty-eight patients with newly-diagnosed Ph-negative B-cell ALL aged 14-59 years of age were enrolled in the study. The protocol allowed for prior treatment with no more than 1 cycle of induction chemotherapy. Patients were required to be eligible for intensive chemotherapy, have an ECOG performance status of ≤ 3, adequate organ function defined as bilirubin ≤ 2 mg/dL, and creatinine ≤ 2 mg/dL. Patients were not permitted to have significant central nervous system pathology.

At baseline, the population had a median age of 34 years (range, 17-59), and the majority (81%) had an ECOG performance score of 0 or 1. The median baseline white blood cell count was 4.1 x 109/L (range, 0.5-553). CNS involvement at the time of diagnosis was observed in 10% of the study population. Fifty-five percent of patients had a CD20 ≥ 20% and 98% had a CD 19 ≥50%.

In terms of karyotype, diploid was most commonly identified (31%), followed by low hypodiploidy/near triploidy (14%), KMT2A rearrangement (9%) complex (7%), and high hyperdiploidy (7%). Thirty-three percent of patients had other karyotypes.

According to cytometry, 19% of patients in the study were CRLF2-positive. Also, 26% of patients tested positive for a TP53 mutation and 8% were positive for a JAK2 mutation.

Treatment in the intensive phase lasted for 4 weeks of therapy. Patients were treated with ofatumumab (Kesimpta) or rituximab (Rituxan) twice per week with hyper-CVAD, methotrexate plus 8 doses of cytarabine. Following the intensive phase, patients received blinatumomab on weeks 2 and 4. In the maintenance phase, patients received 6 doses of mercaptopurine plus vincristine, methotrexate, and prednisone (POMP) on days 1-3, 5-7, 9-11, and 13-15. Additionally, patients were treated with blinatumomab on days 4, 8, and 12 during the maintenance phase, and inotuzumab was administered at 0.3 mg/m2 on days 1 and 8.

After induction, CRs were observed in 80% of patients overall. The CR rate in patients treated with hyper-CVAD plus blinatumomab was 81% compared with 77% among patients treated with hyper-CVAD with sequential blinatumomab plus inotuzumab. MRD negativity after induction was observed in 76% of patients overall. The hyper-CVAD plus blinatumomab arm has a CR rate of 85% after induction vs 63% in the hyper-CVAD with sequential blinatumomab plus inotuzumab group.

The CR at any time was 100% in the overall population as well as in each treatment arm. MRD negativity at any time was 95% overall and 97% for the hyper-CVAD plus blinatumomab compared with 63% in the other treatment arm.

The 30-day mortality was 3% in the overall population, with all deaths occurring in the hyper-CVAD plus blinatumomab arm.

Median follow-up was 34 months (range, 16-61) in the hyper-CVAD plus blinatumomab arm. Of the 38 patients who achieved a CR in the hyper-CVAD plus blinatumomab arm, 5 patients relapsed, 3 died, 13 went on to transplant, and 18 had ongoing CRs at the time of data cutoff.

Among patients treated with hyper-CVAD plus blinatumomab and inotuzumab, the median follow-up was 6 months (range, 3-14). Among the 20 patients who achieved a CR with the regimen, 5 went on to transplant and 15 had ongoing CRs at the time of data cutoff.

The probability of survival and CR durability at 3 years was 85% and 84%, respectively. Investigators also estimate a 1-year OS rate of 100% in the hyper-CVAD plus blinatumomab and inotuzumab arm vs 87% in the hyper-CVAD plus blinatumomab arm.

Further, the efficacy findings show no relapses among patients without baseline high-risk features, and no relapses were observed beyond 2 years.

Only 1 patient in the study discontinued treatment with blinatumomab as a result of recurrent grade 2 neurotoxicity. There were no patients who discontinued inotuzumab due to adverse events, and no cases of hepatic veno-occlusive disease were observed.

Reference

Short NJ, Kantarjian H, Ravandi F, et al. A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol. 2022; 40(suppl 16):7034. doi: 10.1200/JCO.2022.40.16_suppl.7034

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Related Content